China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…
Alzheimer's disease is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing the deterioration of patients’ social and…
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust…
The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…
Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…
Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s…
The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then,…
Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no…
Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population…
Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the growing…
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2029. The treatment of metastatic colorectal cancer is…
Hepatitis B virus (HBV) infection is a major public health burden in China, and chronically infected HBV patients are at a high risk of developing hepatic cirrhosis and hepatocellular carcinoma…
Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…